Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor for the treatment of immuno-inflammatory indications. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey. more
Time Frame | VYNE | Sector | S&P500 |
---|---|---|---|
1-Week Return | 12.5% | -0.33% | -1.49% |
1-Month Return | 0.68% | -4.57% | -0.37% |
3-Month Return | 61.41% | -9.96% | 3.89% |
6-Month Return | 71.68% | -5.67% | 9.34% |
1-Year Return | 18.33% | 2.53% | 25.19% |
3-Year Return | -84.86% | -1.43% | 24.7% |
5-Year Return | -99.28% | 34.73% | 85.39% |
10-Year Return | -99.86% | 102.14% | 187.19% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 1.75M | 20.99M | 14.76M | 477.00K | 424.00K | [{"date":"2019-12-31","value":8.34,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":70.29,"profit":true},{"date":"2022-12-31","value":2.27,"profit":true},{"date":"2023-12-31","value":2.02,"profit":true}] |
Cost of Revenue | 350.00K | 1.39M | 3.35M | - | - | [{"date":"2019-12-31","value":10.45,"profit":true},{"date":"2020-12-31","value":41.58,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Gross Profit | 93.00K | 19.60M | 11.41M | 477.00K | 424.00K | [{"date":"2019-12-31","value":0.47,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":58.2,"profit":true},{"date":"2022-12-31","value":2.43,"profit":true},{"date":"2023-12-31","value":2.16,"profit":true}] |
Gross Margin | 5.31% | 93.37% | 77.31% | 100.00% | 100.00% | [{"date":"2019-12-31","value":5.31,"profit":true},{"date":"2020-12-31","value":93.37,"profit":true},{"date":"2021-12-31","value":77.31,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Expenses | 76.24M | 133.08M | 79.44M | 34.77M | 29.68M | [{"date":"2019-12-31","value":57.29,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":59.69,"profit":true},{"date":"2022-12-31","value":26.13,"profit":true},{"date":"2023-12-31","value":22.3,"profit":true}] |
Operating Income | (76.24M) | (113.47M) | (68.03M) | (34.30M) | (29.26M) | [{"date":"2019-12-31","value":-7624200000,"profit":false},{"date":"2020-12-31","value":-11347500000,"profit":false},{"date":"2021-12-31","value":-6803200000,"profit":false},{"date":"2022-12-31","value":-3429500000,"profit":false},{"date":"2023-12-31","value":-2925800000,"profit":false}] |
Total Non-Operating Income/Expense | 5.08M | (146.74M) | (11.36M) | 363.00K | - | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-2889.74,"profit":false},{"date":"2021-12-31","value":-223.61,"profit":false},{"date":"2022-12-31","value":7.15,"profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Pre-Tax Income | (73.70M) | (255.83M) | (73.78M) | (33.93M) | (27.87M) | [{"date":"2019-12-31","value":-7370300000,"profit":false},{"date":"2020-12-31","value":-25582600000,"profit":false},{"date":"2021-12-31","value":-7377700000,"profit":false},{"date":"2022-12-31","value":-3393200000,"profit":false},{"date":"2023-12-31","value":-2787200000,"profit":false}] |
Income Taxes | (3.24M) | (258.00K) | (448.00K) | 13.00K | 580.00K | [{"date":"2019-12-31","value":-558.45,"profit":false},{"date":"2020-12-31","value":-44.48,"profit":false},{"date":"2021-12-31","value":-77.24,"profit":false},{"date":"2022-12-31","value":2.24,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Income After Taxes | (70.46M) | (255.57M) | (73.33M) | (33.95M) | - | [{"date":"2019-12-31","value":-7046400000,"profit":false},{"date":"2020-12-31","value":-25556800000,"profit":false},{"date":"2021-12-31","value":-7332900000,"profit":false},{"date":"2022-12-31","value":-3394500000,"profit":false},{"date":"2023-12-31","value":"-","profit":true}] |
Income From Continuous Operations | (73.70M) | (255.57M) | (73.33M) | (33.95M) | (29.48M) | [{"date":"2019-12-31","value":-7370300000,"profit":false},{"date":"2020-12-31","value":-25556800000,"profit":false},{"date":"2021-12-31","value":-7332900000,"profit":false},{"date":"2022-12-31","value":-3394500000,"profit":false},{"date":"2023-12-31","value":-2948100000,"profit":false}] |
Income From Discontinued Operations | (29.12M) | (29.12M) | (29.12M) | 10.73M | - | [{"date":"2019-12-31","value":-271.27,"profit":false},{"date":"2020-12-31","value":-271.27,"profit":false},{"date":"2021-12-31","value":-271.27,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (70.46M) | (255.57M) | (73.33M) | (33.95M) | (28.45M) | [{"date":"2019-12-31","value":-7046400000,"profit":false},{"date":"2020-12-31","value":-25556800000,"profit":false},{"date":"2021-12-31","value":-7332900000,"profit":false},{"date":"2022-12-31","value":-3394500000,"profit":false},{"date":"2023-12-31","value":-2845200000,"profit":false}] |
EPS (Diluted) | (222.48) | (103.50) | (23.04) | (11.07) | (7.04) | [{"date":"2019-12-31","value":-22248,"profit":false},{"date":"2020-12-31","value":-10350,"profit":false},{"date":"2021-12-31","value":-2304,"profit":false},{"date":"2022-12-31","value":-1107,"profit":false},{"date":"2023-12-31","value":-704,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
VYNE | |
---|---|
Cash Ratio | 5.54 |
Current Ratio | 5.81 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
VYNE | |
---|---|
ROA (LTM) | -34.54% |
ROE (LTM) | -60.47% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
VYNE | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.17 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.83 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
VYNE | |
---|---|
Trailing PE | 1.74 |
Forward PE | NM |
P/S (TTM) | 76.90 |
P/B | 0.60 |
Price/FCF | NM |
EV/R | 10.04 |
EV/Ebitda | 1.84 |
Vyne Therapeutics Inc (VYNE) share price today is $2.97
Yes, Indians can buy shares of Vyne Therapeutics Inc (VYNE) on Vested. To buy Vyne Therapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in VYNE stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Vyne Therapeutics Inc (VYNE) via the Vested app. You can start investing in Vyne Therapeutics Inc (VYNE) with a minimum investment of $1.
You can invest in shares of Vyne Therapeutics Inc (VYNE) via Vested in three simple steps:
The 52-week high price of Vyne Therapeutics Inc (VYNE) is $3.43. The 52-week low price of Vyne Therapeutics Inc (VYNE) is $1.57.
The price-to-earnings (P/E) ratio of Vyne Therapeutics Inc (VYNE) is 1.7442
The price-to-book (P/B) ratio of Vyne Therapeutics Inc (VYNE) is 0.60
The dividend yield of Vyne Therapeutics Inc (VYNE) is 0.00%
The market capitalization of Vyne Therapeutics Inc (VYNE) is $44.25M
The stock symbol (or ticker) of Vyne Therapeutics Inc is VYNE